News

Fulcrum discontinues pociredir for sickle cell disease following FDA's decision that PRC2 inhibitors carry equivalent malignancy risk regardless of...

Agios licenses SYK inhibitor cevidoplenib from Oscotec for ITP treatment, planning Phase 3 trials based on secondary endpoint data...

Pacira BioSciences posts record $726M revenue in 2025 while facing activist board challenge at June annual meeting.

Intravacc and Primrose Bio renew conjugate vaccine partnership to integrate CRM197 carrier protein supply with manufacturing services.

ViCentra triples manufacturing capacity ahead of German insulin pump expansion, positioning its Kaleido patch pump for scaled commercialization across...

BXCL501 reduces agitation across mild, moderate, and severe baseline cases in at-home trial, with strongest effect in severe episodes.

Zenas BioPharma files FDA application for obexelimab in IgG4-RD, showing 56% reduction in flare risk versus placebo in phase...

Lilly licenses GLP-2 analog sonefpeglutide from Hanmi for $1.26B, betting on intestinal repair applications beyond short bowel syndrome.

NeuroThera Labs gains conditional TSX approval to acquire a majority stake in CliniQuantum, a quantum analytics firm for clinical...

Pacira defends 5x30 strategy against proxy challenge, citing 31% stock gain, record revenues of $726.4M, and accelerating EXPAREL volume...